BioSpace News Archive

PhaseBio today reported financial results for the fourth quarter and full-year ended December 31, 2019, and provided an update on corporate activities.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, provided a business update on the proactive steps it is taking in response to the global COVID-19 pandemic.

Announces publication of accompanying JAMA editorial highlighting important secondary endpoints including congestive heart failure A pabetalone development program moving toward next study to enable a New Drug Application filing CALGARY, Alberta, March 30, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “ Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovas

Inhibition of GAS6/AXL signaling induces ‘BRCAness’ in preclinical model of ovarian cancer, increasing response to platinum chemotherapy and PARP inhibitor Multiple Abstracts Published on Website of the Society for Gynecologic Oncology 2020 Annual Meeting Recorded Webcast and Posters to be Published on Aravive Website HOUSTON, March 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that AVB-500 improves anti-tumor eff

OliX Pharmaceuticals to accelerate the development of effective targeted therapy for liver diseases using AM Chemical’s GalNAc-conjugation technology SUWON, Republic of Korea, March 30, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc . (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has signed an exclusive worldwide licensing agreement with AM Chemicals (AMC) for the rights to patents and know-how encompassing the technology to conjugate N-

Lumos Pharma, Inc. has announced the appointment of Joseph S. McCracken, DVM, MS to the company’s Board of Directors, effective March 23, 2020. Dr. McCracken has extensive experience in the pharmaceutical and biotechnology industry, with prominent roles in business development, commercial development, and positions as board member for severa

I-Mab (the “Company”)(Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced a strategic partnership with Kalbe Genexine Biologics (“KG Bio”),

Immunovia invites you to a teleconference for all stakeholders and media on Wednesday, April 1, 2020 at 16:30 CET.

The device is designed to restore vision to persons blinded by age-related macular degeneration and retinitis pigmentosa

Article reviews mechanisms of action (MOA) of medications used in the treatment of patients with narcolepsy and clinical implications